Over 90 Total Lots Up For Auction at One Location - WA 04/08

Five-year study data confirm positive outcomes for patients when Abbott diagnostic tool was used to guide heart stenting

Press releases may be edited for formatting or style | May 22, 2018 Cardiology

Patients who underwent FFR-guided PCI in combination with medical therapy had fewer heart attacks than those who received medical therapy alone with 8.1 percent of patients (36) in the FFR-guided PCI group experiencing a heart attack compared to 12.0 percent (53) in the medical therapy alone group (p=0.049). Death from any cause occurred in 5.1 percent of patients in the FFR-PCI group (23) and in 5.2 percent of patients (23) in the medical therapy alone group.

Resting Full-Cycle Ratio
In a separate study presented at the meeting, promising data were presented for Abbott's Resting Full-Cycle Ratio (RFR) diagnostic test, which uses a different approach to FFR that assesses the heart at rest rather than at stress. RFR is a novel measurement that has the potential to identify significant narrowing of arteries that would be missed by other resting measures due to differences in its algorithm. RFR may be more convenient for patients than FFR as it does not require the use of vasodilators, medicines that dilate blood vessels during the test causing the heart to be stressed. The VALIDATE RFR study results were presented by Ziad Ali, M.D., D. Phil, from Columbia University Medical Center in New York.

The VALIDATE RFR study included 672 coronary artery narrowings from 504 patients and compared RFR with an instant wave-free ratio (iFR) diagnostic that also measures blood flow while the heart is at rest. The study aimed to validate the RFR algorithm, which differs from other resting measurements because it identifies critical narrowings by taking measurements across the full heart cycle.

Analysis showed RFR was highly correlated to iFR (R2=0.99, p<0.001) and diagnostically equivalent within 1 percent to iFR (p=0.03), suggesting that both tests would lead to the same clinical decision most of the time. RFR is currently pending 510(k) and CE Mark.

"We're committed to bringing life-saving technologies to people with heart disease including diagnostic tools that help doctors make treatment decisions, which lead to better outcomes for patients," said Charles Simonton, M.D., chief medical officer of Abbott's vascular business. "These results continue to support that measuring blood flow prior to implanting a stent is an effective way to help doctors determine which vessels to treat, and can improve patient outcomes over medical therapy alone."


About Abbott:
At Abbott, we're committed to helping people live their best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world -- in nutrition, diagnostics, medical devices and branded generic pharmaceuticals -- that create more possibilities for more people at all stages of life. Today, 99,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

SOURCE Abbott

Back to HCB News

You Must Be Logged In To Post A Comment